Pathogen-reduction systems for blood components: the current position and future trends.
about
Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical useBlood transfusion safety in Africa: a literature review of infectious disease and organizational challengesUltraviolet B light-exposed human platelets mediate acute lung injury in a two-event mouse model of transfusion.Main Properties of the THERAFLEX MB-Plasma System for Pathogen ReductionThe Effects of Ultraviolet Light and Riboflavin on Inactivation of Viruses and the Quality of Platelet Concentrates at Laboratory Scale.Controlled inactivation of recombinant viruses with vitamin B2.Transfusion safety in francophone African countries: an analysis of strategies for the medical selection of blood donors.Combination of photodynamic therapy and immunomodulation: current status and future trendsRecommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasmaDuration of red blood cell storage and inflammatory marker generationTransfusion medicine and proteomics. Alliance or coexistence?A general change of the platelet transfusion policy from apheresis platelet concentrates to pooled platelet concentrates is associated with a sharp increase in donor exposure and infection rates.Proteomics of blood and derived products: what's next?Viral inactivation in hemotherapy: systematic review on inactivators with action on nucleic acidsLaboratory Evaluation of the Effectiveness of Pathogen Reduction Procedures for BacteriaAn effective and potentially safe blood disinfection protocol using tetrapyrrolic photosensitizers.Riboflavin-ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells.Bio-inspired nanomedicine strategies for artificial blood components.The platelets' perspective to pathogen reduction technologies.Pathogen inactivation by riboflavin and ultraviolet light illumination accelerates the red blood cell storage lesion and promotes eryptosis.In vitro function of platelets treated with ultraviolet C light for pathogen inactivation: a comparative study with nonirradiated and gamma-irradiated platelets.Photochemically inactivated hepatitis B virus promotes upregulation of Th1-type cytokines.Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding.Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment.Intravenous synthetic platelet (SynthoPlate) nanoconstructs reduce bleeding and improve 'golden hour' survival in a porcine model of traumatic arterial hemorrhage.Detection of nucleic acid lesions during photochemical inactivation of RNA viruses by treatment with methylene blue and light using real-time PCR.Proteomic analysis of platelets treated with gamma irradiation versus a commercial photochemical pathogen reduction technology.Establishment of the first international repository for transfusion-relevant bacteria reference strains: ISBT working party transfusion-transmitted infectious diseases (WP-TTID), subgroup on bacteria.Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage.p38MAPK is involved in apoptosis development in apheresis platelet concentrates after riboflavin and ultraviolet light treatment.
P2860
Q26741073-524153DB-AD92-409D-A786-0E31CA723F94Q26866294-BA391F7F-E637-4378-BA70-6FDB0D220FB1Q33394914-88370887-6B32-4317-86F8-EA4752D6A6DCQ33396311-A04E27D2-46D1-4540-AC8A-5280EFFD66E2Q35682144-8A25D4D7-7DCB-4551-921B-24B80F477F2EQ36593399-FA93B98E-FBA7-4F68-BBBC-ACD46515E364Q36890459-D0616DC4-2F19-4167-AB62-E08C56539616Q36922722-E7A45AF5-E08C-44D2-82D2-2B62EA602D9AQ37062415-BA7FFE11-6CCA-4906-944A-5A188B8D5228Q37679824-2F34ADE1-2034-4169-A28B-4C6FBB8246C3Q37770409-0C92C56E-687D-4C4B-8CDF-B02B884BBC8EQ37867952-0354481E-EE6E-4A1D-91F3-84791F19B283Q37956664-8EC5CEF9-7AA5-4750-AB5E-998652EB59DEQ38050757-21A1D420-AD7B-4F54-A598-C896A7437C81Q38667338-3F4E293F-FAF7-4CA2-8FBA-6C2287694F79Q38750230-9DBC9137-1585-4EB8-A5B2-17CB39E18717Q38934537-B566889B-DB4F-4209-9AC9-1FC30F72FBBAQ39179984-D294AFAC-8A35-4827-A125-1A2EC9C54FDDQ40273685-616855DD-440B-4AB8-9BF7-05D7C77F4D37Q40395209-94FF30F2-8C08-4148-98DE-0E3FA18913EDQ42176554-80EC5154-E724-470D-BDCB-902018E357B3Q45357674-91EF3DF1-1C2B-40CF-A8FF-3DF6B247FBE7Q47324534-5016EB12-2123-4DF7-85B0-C223DDABD1AFQ47572436-3B116C84-7136-4F51-B2C3-261F96C80F40Q49958847-A76CCCC9-C7EF-43AB-8FA6-23EAD0A54277Q50439879-1C01C51E-2044-4651-9B61-FF7ECD4EBED0Q51540517-FE899EE3-151E-4F48-8027-1B87EBD88DBDQ53150327-B6E1F7A1-C0E8-4C4E-9178-C1E6D3847431Q53877861-96F9520B-DAF1-495A-913C-ED6FD9BBB2BBQ54310409-76B7F2F7-AF25-4828-B6CA-4D6B5CA947A3
P2860
Pathogen-reduction systems for blood components: the current position and future trends.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Pathogen-reduction systems for blood components: the current position and future trends.
@ast
Pathogen-reduction systems for blood components: the current position and future trends.
@en
type
label
Pathogen-reduction systems for blood components: the current position and future trends.
@ast
Pathogen-reduction systems for blood components: the current position and future trends.
@en
prefLabel
Pathogen-reduction systems for blood components: the current position and future trends.
@ast
Pathogen-reduction systems for blood components: the current position and future trends.
@en
P1476
Pathogen-reduction systems for blood components: the current position and future trends.
@en
P2093
Gracinda de Sousa
Jerard Seghatchian
P304
P356
10.1016/J.TRANSCI.2006.10.002
P577
2006-11-15T00:00:00Z